BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23613388)

  • 1. Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90.
    Chen TW; Liang YN; Feng D; Tao LY; Qi K; Zhang HY; Wang HX; Lin QS; Kong H
    J BUON; 2013; 18(1):51-6. PubMed ID: 23613388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
    Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway].
    Lin YJ; Huang YH; Zhen YZ; Liu XJ; Zhen YS
    Yao Xue Xue Bao; 2008 Nov; 43(11):1099-105. PubMed ID: 19239027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
    Li X; Deng HY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line].
    Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):503-6. PubMed ID: 17147113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
    Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
    Sun J; Xu Y; Song S; Wu Z; Duan H
    Pharm Biol; 2011 Nov; 49(11):1167-72. PubMed ID: 22014264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis.
    Zhang N; Kong X; Yan S; Yuan C; Yang Q
    Cancer Sci; 2010 Nov; 101(11):2375-83. PubMed ID: 20718753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
    Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
    Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.